Меню
Идёт набор NCT04956549

Reducing African American's Alzheimer's Risk Through Exercise-Mild Cognitive Impairment (RAATE-MCI)

Без фазы С лечением Dementia of Alzheimer Type

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Physical activity program, Successful Aging.
Кому может быть актуально
Состояния в реестре: Dementia of Alzheimer Type. Базовые параметры: от 60 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
США
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

Reducing African Americans' Alzheimer's Disease Risk Through Exercise-Mild Cognitive Impairment Cohort

Обзор

The RAATE-MCI proposal is designed to determine the effects of physical activity on risk factors for Alzheimer's Disease in older African American adults. The study will compare a physical activity program to an active control group. RAATE-MCI is a 52-week randomized controlled trial. 144 African American adults aged 60 and older will be recruited.

Подробное описание

Regular physical activity has proven to be a safe and effective means to enhance cognitive function in older adults ranging from cognitively healthy to mildly cognitively impaired. A large body of existing data suggests that exercise improves cardiovascular and cerebrovascular functioning and thus has the potential to enhance perivascular clearance of amyloid and reduce chronic brain tissue ischemia, among other beneficial effects. Therefore, our study is focused on physical activity promotion, a potent approach to modifying multiple neurobiological pathways implicated in Alzheimer's Disease. RAATE-MCI is a 52-week randomized controlled trial that will assign insufficiently active African American adults aged 60 and older to one of two groups: a physical activity intervention or a successful aging (active control) group. Outcome measures will be collected at baseline, 24-,and 52-weeks. 144 older African American adults will be recruited.

Intervention will consist of one of two groups: a 150 minutes of physical activity (PA) per week or successful aging (SA) group. All physical activity and successful aging group sessions will be conducted at Pennington Biomedical or at local community facilities that include branches of the YMCA and community centers.

Вмешательства

  • Поведенческое Physical activity program
    Supervised group sessions will be held twice per week for approximately 52 weeks. Each physical activity session will last slightly approximately 80 minutes and will consist of aerobic, strength, flexibility, and balance training. The 80 minutes of activity consists of a 5 minute warm-up, 45 minutes of aerobic training, 15 minutes of strength training, 10 minutes of balance training, and a 5 minute cool-down. The physical activity group will target 150 minutes of moderate to vigorous aerobic phy
  • Поведенческое Successful Aging
    The successful aging group will be based on a low-intensity activity program and a healthy aging educational component. Sessions will be approximately 60 minutes in duration and will occur once per week for the first 6 months and then every other week for the remainder 6 months of the study. The physical activities will include stretching, balance training, flexibility, relaxation, and practicing activities of daily living. The successful aging education component will cover topics including avo

Первичные конечные точки

  • Change in executive function [Срок оценки: Baseline, 24 weeks, 52 weeks]
  • Change in episodic memory [Срок оценки: Baseline, 24 weeks, 52 weeks]
Вторичные конечные точки (12)
  • Change in cognitive status [Срок оценки: Baseline, 24 weeks, 52 weeks]
  • Change in glucose [Срок оценки: Baseline, 24 weeks, 52 weeks]
  • Change in time spent in physical activity [Срок оценки: Baseline, 24 weeks, 52 weeks]
  • Change in cardiorespiratory fitness [Срок оценки: Baseline, 24 weeks, 52 weeks]
  • Change in physical function-NIH Toolbox [Срок оценки: Baseline, 24 weeks, 52 weeks]
  • Change in telomere length [Срок оценки: Baseline, 24 weeks, 52 weeks]
  • Change in weight [Срок оценки: Baseline, 24 weeks, 52 weeks]
  • Change in brain structure [Срок оценки: Baseline, 24 weeks, 52 weeks]
  • Changes in brain function [Срок оценки: Baseline, 24 weeks, 52 weeks]
  • Change in lipoproteins [Срок оценки: Baseline, 24 weeks, 52 weeks]
  • APOE genotype [Срок оценки: Baseline]
  • Change in physical activity [Срок оценки: Continuously for 52 weeks]

Критерии участия

Критерии включения

  • are African American (self-identify)
  • are 60 and older
  • are physically capable of exercise
  • are willing to accept randomization
  • are willing to attend group sessions
  • plan to live in the study area over the next 13 months and capable of traveling to designated study facility for clinic visits and intervention sessions for the next year
  • are free of conditions (e.g. uncontrolled asthma, severe sickle cell disease, etc.) that would make regular exercise unsafe as deemed by the medical investigator
  • have not engaged in regular physical activity
  • have a Short Physical Performance Battery ≥4
  • physically capable of exercise
  • are unable to utilize devices and/or applications as required for study participation
  • willing to attend group sessions
  • willing to allow researchers to use data for research purposes after study participation is completed
  • meet criteria for MCI as defined by the NIA-AA research framework a. cognitive performance below normal range (score < 1.5 SDs below the mean on NIH Toolbox scores for their age and sex on at least one of the subtests)

Критерии исключения

  • have cognitive impairment that would interfere with participating in a group discussion

a. cognitive performance in the demented range (score < 3 SDs below the mean on NIH Toolbox scores for their age and sex on at least one of the subtests)

  • meet criteria for dementia
  • are unwilling to give written informed consent or accept randomization in either study group
  • are too active (as defined by ≥10 min bouts of MVPA as measured by Actigraph) if:
  • Sum of MVPA bouts for the 7 day wear period ≥40 mins
  • Or ≤40 mins of MVPA 10min bouts AND ≥3 days of bouts
  • have uncontrolled hypertension (systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 90 mmHg).
  • have had a myocardial infarction, major heart surgery (i.e., valve replacement or bypass surgery), stroke, deep vein thrombosis, pulmonary embolus, hip fracture, hip or knee replacement, or spinal surgery in the past 6 months
  • are undergoing cardiopulmonary rehabilitation
  • have uncontrolled diabetes that in the judgment of the MI may interfere with study participation
  • have clinically diagnosed osteoporosis that in the judgment of the MI may interfere with study participation
  • are currently enrolled in another randomized trial involving lifestyle or pharmaceutical interventions
  • have another member of the household that is a participant in RAATE or RAATE MCI
  • refuse to participate in the study without disclosure of their amyloid PET scan results
  • refuse to allow anonymized versions of their study data for research after this study is completed.
  • have other medical, psychiatric, or behavioral factors that in the judgment of the Principal or Medical Investigator may interfere with study participation or the ability to follow the intervention protocol

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Рандомизированное
Модель
Параллельные группы
Маскирование
Простое слепое
Основная цель
Профилактика

Центры проведения

США · 1 центр
  • Pennington Biomedical Research — Baton Rouge

Идентификаторы

NCT: NCT04956549 · PBRC 2020-013 · R01AG067765-01

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗